RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report

Cellular Oncology

Volumn 38, Issue 4, 2015, Pages 319-325

  Zeng, Chuan ^a   Fan, Weidong ^a   Zhang, Xianquan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Gemcitabine; Non small cell lung cancer; Prognostic meta analysis; RRM1 expression

Indexed keywords

GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CNKI DATABASE; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEB OF SCIENCE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; METABOLISM; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84938553598     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0225-9     Document Type: Article

References (32)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127, 2893–2917 (2008)
2. Q. Wu, Y.F. Chen, J. Fu, Q.H. You, S.M. Wang, X. Huang, X.J. Feng, S.H. Zhang, Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell Oncol 37, 399–407 (2014)
3. A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell Oncol 36, 265–75 (2013)
4. N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol 36, 277–288 (2013)
5. R.T. Greenlee, M.B. Hill-Harmon, T. Murray, M. Thun, Cancer statistics. CA Cancer J Clin 5, 15–36 (2001)
6. K. Ohashi, L.V. Sequist, M.E. Arcila, T. Moran, J. Chmielecki, Y.L. Lin, Y. Pan, L. Wang, E. de Stanchina, K. Shien, K. Aoe, S. Toyooka, K. Kiura, L. Fernandez-Cuesta, P. Fidias, J.C. Yang, V.A. Miller, G.J. Riely, M.G. Kris, J.A. Engelman, C.L. Vnencak-Jones, D. Dias-Santagata, M. Ladanyi, W. Pao, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109, 2127–2133 (2012)
7. T.K. Owonikoko, M. Behera, Z. Chen, C. Bhimani, W.J. Curran, F.R. Khuri, S.S. Ramalingam, A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 7, 866–872 (2012)
8. B. Besse, K.A. Olaussen, J.C. Soria, ERCC1 and RRM1: ready for prime time? J Clin Oncol 31, 1050–1060 (2013)
9. G. Bepler, M.A. Garcia-Blanco, Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci U S A 91, 5513–5517 (1994)
10. G. Bepler, A. Gautam, L.M. McIntyre, A.F. Beck, D.S. Chervinsky, Y.C. Kim, D.M. Pitterle, A. Hyland, Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20, 1353–1360 (2002)
11. D.M. Pitterle, Y.C. Kim, E.M. Jolicoeur, Y. Cao, K.C. O’Briant, G. Bepler, Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome 10, 916–922 (1999)
12. G.R. Simon, M. Begum, G. Bepler, Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol 4, 51–59 (2008)
13. J.J. Lee, C.H. Maeng, S.K. Baek, G.Y. Kim, J.H. Yoo, C.W. Choi, Y.H. Kim, Y.T. Kwak, D.H. Kim, Y.K. Lee, J.B. Kim, S.Y. Kim, The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70, 205–210 (2010)
14. R. Rosell, G. Scagliotti, K.D. Danenberg, R.V. Lord, G. Bepler, S. Novello, J. Cooc, L. Crinò, J.J. Sánchez, M. Taron, C. Boni, F. De Marinis, M. Tonato, M. Marangolo, F. Gozzelino, F. Di Costanzo, M. Rinaldi, D. Salonga, C. Stephens, Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22, 3548–3553 (2003)
15. J. Souglakos, I. Boukovinas, M. Taron, P. Mendez, D. Mavroudis, M. Tripaki, D. Hatzidaki, A. Koutsopoulos, E. Stathopoulos, V. Georgoulias, R. Rosell, Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98, 1710–1715 (2008)
16. C. Su, S. Zhou, L. Zhang, S. Ren, J. Xu, J. Zhang, M. Lv, J. Zhang, C. Zhou, ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 28, 1411–1417 (2011)
17. A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25, 603–605 (2010)
18. G. Wells, B. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2003. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
19. Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, G. Bepler, DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356, 800–808 (2007)
20. W. Gong, X. Zhang, J. Wu, L. Chen, L. Li, J. Sun, Y. Lv, X. Wei, Y. Du, H. Jin, J. Dong, RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 75, 374–380 (2012)
21. S. Michiels, P. Piedbois, S. Burdett, N. Syz, L. Stewart, J.P. Pignon, Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21, 119–125 (2005)
22. X. Qin, W. Yao, W. Li, X. Feng, X. Huo, S. Yang, H. Zhao, X. Gu, ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Tumour Biol 35, 4697–4704 (2014)
23. Y. Yang, L. Xian, The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 35, 2905–2921 (2014)
24. S.H. Lee, K.B. Noh, J.S. Lee, E.J. Lee, K.H. Min, G.Y. Hur, S.H. Lee, S.Y. Lee, J.H. Kim, S.Y. Lee, C. Shin, J.J. Shim, C.H. Kim, K.H. Kang, K.H. In, Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81, 102–108 (2013)
25. G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, G. Simon, RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non–small-cell lung cancer. J Clin Oncol 24, 4731–4737 (2006)
26. I. Boukovinas, C. Papadaki, P. Mendez, M. Taron, D. Mavroudis, A. Koutsopoulos, M. Sanchez-Ronco, J.J. Sanchez, M. Trypaki, E. Staphopoulos, V. Georgoulias, R. Rosell, J. Souglakos, Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PloS ONE 3, e3695 (2008)
27. Z. Gao, B. Han, J. Shen, A. Gu, H. Zhong, Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients. Chin J Lung Can 14, 340–344 (2011)
28. B. Jiang, C. Xu, W. He, C. Yang, J. Zhao, Analysis of RRM1 expression and efficacy of gemcitabine in advanced non-small cell lung cancer. Can Res Prev Treat 1, 68–71 (2013)
29. L. Li, X. Liu, Correlation of expression of ERCC1/RRM1 with cisplatin combined with gemcitabine chemotherapy sensitivity and prognosis in non-small cell lung cancer. Bull Acad Mil Med Sci 34(3), 265–268 (2010)
30. J. Liang, Y. Deng, W. Feng, W. Hu, Z. Chen, Y. Tang, H. Zhang, H. Xian, S. Zhang, The study of the relationship between RRM1 protein expression and the efficacy of gemcitabine-containing regiment for the first-line treatment of advanced non-small cell lung cancer. Guid Chin Med 10, 10–11 (2012)
31. H. Liu, H. Wang, J. Yang, RRM1 expression and efficacy analysis of gemcitabine in advanced non-small cell lung cancer. Pract Prev Med 16, 11–14 (2009)
32. L. Wang, G. Zhang, J. Chen, J. Li, M. Li, Y. Wang, N. Xu, J.Z. Shen, Effect of RRM1 and BRCA1 expressions on efficiency of gemcitabine and platinum in patients with advanced non-small cell lung cancer. Chin Pharm J 20, 1557–1580 (2010)